BioSpace News Archive

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced today that the Company has amended the previously announced 2020 option and license agreement with AbbVie for acazicolcept.

Danaher Corporation announced that it will webcast its quarterly earnings conference call for the fourth quarter 2023 on Tuesday, January 30, 2024 beginning at 8:00 a.m. ET and lasting approximately one hour.

Geron Corporation, a late-stage clinical biopharmaceutical company, reported that it has granted non-statutory stock options to purchase an aggregate of 417,490 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

Aptorum Group Limited announced the results of its 2023 annual general meeting of shareholders, which was held on December 20, 2023, in London.

Justera Health Ltd. (CSE: VTAL) (OTC Pink: SCRSF) (“Justera” or the “Company”) is pleased to announce that subsequent to the news release dated November 2, 2023, the Company’s wholly-owned subsidiary

Theravance Biopharma, Inc. (“Theravance” or the “Company”) (NASDAQ: TBPH) today announced the appointment to its Board of Directors of Jeremy Grant, who serves as a Special Advisor to Irenic Capital Management LP (“Irenic”).

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved Ionis and AstraZeneca’s WAINUA™ (eplontersen) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, commonly referred to as hATTR-PN or ATTRv-PN.

Medicenna Therapeutics Corp. announced that it has received conditional approval from the Toronto Stock Exchange to extend the expiry date of the common share purchase warrants of the Company originally issued on December 21, 2018.

IRLAB Therapeutics AB announced that the company’s drug candidate IRL757 has completed all preclinical studies and development work necessary to start Phase I.

Alterity Therapeutics, a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, announced the appointment of Phillip Hains as the Company’s new Chief Financial Officer, effective 31 January 2024.